Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nat Prod Res ; 36(12): 3043-3053, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-34498976

RESUMEN

Juncus effusus L. (J. effusus) is a Traditional Chinese Medicine (TCM) that has long been used for dealing with gynaecological disorders, such as relieving insomnia, preventing tinnitus, reducing edema with diuretic effect. In our course of evidence-based medical research focused on this herb, one new phenanthrene, Junfusol B (2), together with seventeen known compounds were isolated and identified. All the structures of these compounds were elucidated by spectroscopic methods. The absolute stereochemistry of compounds 1 and 2 was further determined by comparing their calculated and experimental Electronic Circular Dichroism (ECD) spectra and optical rotation (OR) values. The isolates were evaluated for their estrogenic and anti-inflammatory activities which were considered as relevant etiological factors of insomnia, tinnitus and edema in the ancient TCM theory. The results revealed that most of the obtained phenanthrenes in this work were found exerting agonistic effects on estrogen receptor. This is the first report to declare the exact estrogen-regulating potential among this type of compounds from J. effusus. Moreover, phenanthrenes 3 - 7 exhibited significant inhibitions on superoxide anion generation and elastase release in fMLP/CB-induced human neutrophilic inflammation model. J. effusus may be developed as a complementary agent utilized in menopausal multiple syndromes.


Asunto(s)
Magnoliopsida , Fenantrenos , Trastornos del Inicio y del Mantenimiento del Sueño , Acúfeno , Antiinflamatorios/química , Antiinflamatorios/farmacología , Edema , Humanos , Magnoliopsida/química , Fenantrenos/química , Fenantrenos/farmacología
2.
J Food Drug Anal ; 27(1): 240-248, 2019 01.
Artículo en Inglés | MEDLINE | ID: mdl-30648577

RESUMEN

Type 2 diabetes mellitus (T2DM) is a chronic disease characterized by hyperglycemia that can lead to long-term complications including heart diseases, stroke, retinopathy, and renal failure. Treatment strategies include stimulating glucose uptake and controlling blood glucose level. Bofutsushosan (BOF) and Daisaikoto (DAI) are two herb-based kampo medicines that have been demonstrated to improve metabolism-associated disorders including obesity, hyperlipidemia, and nonalcoholic fatty liver. Given their bioactivities against metabolic syndromes, we explored in this study the effect of BOF and DAI extracts on glucose absorption and used them as source to identify phytochemical stimulator of glucose absorption. Glucose uptake and mechanistic studies were evaluated in differentiated C2C12 skeletal muscle cells, and HPLC analysis was used to determine the molecular bioactive constituents. Our results indicated that the ethanolic extracts of BOF and DAI (BOFEE and DAIEE, respectively) enhanced the glucose uptake ratio in the differentiated C2C12 cells, and further analysis identified the flavone baicalin as a major constituent capable of efficiently stimulating glucose absorption. Mechanistic studies revealed that the effect from baicalin involved the activation of IRS-1 and GLUT-4, and implicated the AMPK, PI3K/Akt, and MAPK/ERK signaling cascades. Due to its potency, we suggest that baicalin merit further evaluation as a potential candidate anti-hyperglycemic agent for the treatment and management of T2DM.


Asunto(s)
Medicamentos Herbarios Chinos/farmacología , Flavonoides/farmacología , Glucosa/metabolismo , Hipoglucemiantes/farmacología , Insulina/metabolismo , Animales , Línea Celular , Medicamentos Herbarios Chinos/química , Flavonoides/análisis , Transportador de Glucosa de Tipo 4/genética , Transportador de Glucosa de Tipo 4/metabolismo , Hipoglucemiantes/química , Ratones , Fosfatidilinositol 3-Quinasas/genética , Fosfatidilinositol 3-Quinasas/metabolismo , Transducción de Señal/efectos de los fármacos
3.
Biomed Eng Online ; 14: 105, 2015 Nov 18.
Artículo en Inglés | MEDLINE | ID: mdl-26582033

RESUMEN

BACKGROUND: Although various alterative models of therapy are used for cartilage repair, no definite conclusion has been reached. Glucosamine (GlcN) is widely used as a nutritional supplement. However, the clinical- evidence-based outcome of GlcN administration remains controversial. N-acetyl-D-glucosamine (GlcNAc), a derivative of GlcN, shows chondroprotective activity and mediates the activation of articular chondrocytes. Therefore, we investigated the effect of intra-articular administration of GlcNAc in rabbits' knee joints with experimental full-thickness articular cartilage (FTAC) defects. METHODS: Twelve male adult New Zealand white rabbits, providing 24 knees, were used in this study. FTAC defects were created in the high-weight-bearing area of the medial femoral condyles of bilateral knees. All rabbits were randomly allocated to analysis at postsurgical week 4 or postsurgical week 12. In the week 4 group, rabbits' knees (six per group) were intra-articularly injected with normal saline or with GlcNAc twice per week for 3 weeks, beginning 1 week postoperatively. In the week 12 group, the rabbits' knees (six in each group) were intra-articularly injected with normal saline or with GlcNAc twice per week for 4 weeks, beginning 1 week postoperatively. Rabbits were sacrificed at 4 or 12 weeks after surgery for macroscopic, histological and radiological examinations of the knee joints. RESULTS: All rabbits had no systemic or local adverse effects. The saline and GlcNAc groups showed visible differences in healing of the FTAC defect at the end of testing. At week 4, the GlcNAc group had a higher level of collagen type II (COL II) and showed up-regulated production of transforming growth factor (TGF)-ß2 and TGF-ß3, suggesting the involvement of endogenous growth factors. At week 12, the GlcNAc group displayed formation of hyaline-like cartilage regeneration with mature chondrocytes (SOX9+), robust glycosaminoglycan (GAG) content, and positive COL II content in both the adjacent cartilage and reparative sites. However, the saline group demonstrated mainly fibrocartilage scar tissue, indicating COL I expression. Furthermore, the GlcNAc group had significantly higher bone volume per tissue volume and higher trabecular thickness than the saline group. CONCLUSIONS: Intra-articular GlcNAc may promote the repair of experimental FTAC defects in the rabbit knee joint model.


Asunto(s)
Acetilglucosamina/farmacología , Cartílago Articular/efectos de los fármacos , Articulación de la Rodilla/efectos de los fármacos , Acetilglucosamina/administración & dosificación , Animales , Cartílago Articular/diagnóstico por imagen , Cartílago Articular/patología , Inyecciones , Masculino , Conejos , Microtomografía por Rayos X
4.
J Hepatol ; 62(3): 541-8, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25450204

RESUMEN

BACKGROUND & AIMS: A vaccine against hepatitis C virus (HCV) is unavailable and cost-effective antivirals that prevent HCV infection and re-infection, such as in the transplant setting, do not exist. In a search for novel and economical prophylactic agents, we examined the antiviral activity of saikosaponins (SSa, SSb2, SSc, and SSd) from Bupleurum kaoi root (BK) as entry inhibitors against HCV infection. METHODS: Infectious HCV culture systems were used to examine the effect of saikosaponins on the complete virus life cycle (entry, RNA replication/translation, and particle production). Antiviral activity against various HCV genotypes, clinical isolates, and infection of primary human hepatocytes were also evaluated. RESULTS: BK and the saikosaponins potently inhibited HCV infection at non-cytotoxic concentrations. These natural agents targeted early steps of the viral life cycle, while leaving replication/translation, egress, and spread relatively unaffected. In particular, we identified SSb2 as an efficient inhibitor of early HCV entry, including neutralization of virus particles, preventing viral attachment, and inhibiting viral entry/fusion. Binding analysis, using soluble viral glycoproteins, demonstrated that SSb2 acted on HCV E2. Moreover, SSb2 inhibited infection by several genotypic strains and prevented binding of serum-derived HCV onto hepatoma cells. Finally, treatment with the compound blocked HCV infection of primary human hepatocytes. CONCLUSIONS: Due to its potency, SSb2 may be of value for development as an antagonist of HCV entry and could be explored as prophylactic treatment during the course of liver transplantation.


Asunto(s)
Antivirales/farmacología , Hepacivirus/efectos de los fármacos , Hepacivirus/fisiología , Ácido Oleanólico/análogos & derivados , Saponinas/farmacología , Internalización del Virus/efectos de los fármacos , Animales , Antivirales/aislamiento & purificación , Antivirales/toxicidad , Bupleurum , Línea Celular , Hepatitis C/prevención & control , Hepatocitos/efectos de los fármacos , Hepatocitos/virología , Humanos , Trasplante de Hígado , Masculino , Ácido Oleanólico/aislamiento & purificación , Ácido Oleanólico/farmacología , Ácido Oleanólico/toxicidad , Extractos Vegetales/aislamiento & purificación , Extractos Vegetales/farmacología , Ratas , Ratas Sprague-Dawley , Saponinas/aislamiento & purificación , Saponinas/toxicidad , Virión/efectos de los fármacos , Replicación Viral/efectos de los fármacos
5.
Int J Cardiol ; 127(3): 337-41, 2008 Jul 21.
Artículo en Inglés | MEDLINE | ID: mdl-17659795

RESUMEN

BACKGROUND: Postprandial hypertriglyceridemia is known to cause endothelial dysfunction and increased oxidative stress. Oral supplements of l-arginine have been found to improve endothelial function. However, the effects of supplements of l-arginine on the influences of postprandial hypertriglyceridemia were not studied before. METHODS: Forty young healthy men without any risk factors were equally divided into two groups. l-arginine group (age 22+/-1 years, body mass index 23.5+/-1.2 kg/m(2)) received a standard high-fat meal with 15 g oral l-arginine. Control group (age 22+/-1 years, body mass index 23.8+/-0.9 kg/m(2)) received a standard high-fat meal with placebo. A standard high-fat meal consisted of 900 kcal and 50 g of fat. Flow-mediated vasodilation (FMD), von Willebrand factor (vWF), p-Selectin, and glutathione peroxidase (GSH-Px) were measured before and 2 h after the high-fat meal. RESULTS: Serum triglyceride levels were significantly increased 2 h after the high-fat meal in both groups. In the control group, FMD (10.5+/-1.2% vs. 6.8+/-1.4%, p<0.001) and GSH-Px (23.5+/-6.2 vs. 21.9+/-5.0 mug/ml, p=0.029) were significantly decreased after the high-fat meal. P-Selectin (20.0+/-7.7 vs. 25.9+/-10.5 mg/l, p=0.025) and vWF (731.2+/-131.5 vs. 934.9+/-133.8 mU/ml, p<0.001) were significantly increased after the high-fat meal. In the l-arginine group, FMD (10.3+/-1.3 vs. 9.3+/-0.9%, p<0.001) was slightly but significantly decreased after the high-fat meal but not GSH-Px (23.6+/-3.6 vs. 23.0+/-4.8%, p=0.468). P-Selectin (20.1+/-5.9 vs. 25.7+/-10.2 mg/l, p=0.001) and vWF (793.2+/-146.0 vs. 944.4+/-136.8 mU/ml, p<0.001) were significantly increased after the high-fat meal. Degree of FMD attenuation following the high-fat meal was significantly less in the l-arginine group (1.0+/-0.9 vs. 3.8+/-1.5%, p<0.001). CONCLUSIONS: Concomitant supplements of l-arginine improved endothelial dysfunction and oxidative stress induced by postprandial hypertriglyceridemia. However, changes of p-Selectin and vWF were not affected by supplements of l-arginine with the high-fat meal.


Asunto(s)
Arginina/administración & dosificación , Grasas de la Dieta/administración & dosificación , Suplementos Dietéticos , Endotelio Vascular/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Adulto , Grasas de la Dieta/efectos adversos , Endotelio Vascular/fisiología , Humanos , Hipertrigliceridemia/sangre , Hipertrigliceridemia/prevención & control , Masculino , Estrés Oxidativo/fisiología , Periodo Posprandial/efectos de los fármacos , Periodo Posprandial/fisiología , Vasodilatación/efectos de los fármacos , Vasodilatación/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA